Hypomorphic ATP11c is a novel regulator of decreased efficacy of transfused red blood cells in humans and mice

功能减弱的ATP11c是人和小鼠输注红细胞疗效降低的新型调节因子。

阅读:1

Abstract

Chronic red blood cell (RBC) transfusion sustains patients with diverse hematologic disorders, but repeated transfusion leads to iron overload and alloimmunization. Reducing transfusion burden requires identifying donor units that circulate more effectively after storage, yet determinants of this variability remain incompletely defined. Here, we integrate forward genetics in mice, multi-omics analyses of over 13,000 human donors, and studies of two families with hereditary ATP11c mutations to reveal a central role for this phospholipid flippase in transfusion efficacy. We show that common ATP11C variants, including the missense SNP V972M, and rare familial loss-of-function alleles impair RBC survival by disrupting membrane lipid remodeling and cytoskeletal stability-a mechanism distinct from oxidative damage pathways. Together, these findings establish ATP11c as a novel determinant of transfusion outcomes across species and genetic contexts, and highlight opportunities for donor stratification and improved storage technologies to advance precision transfusion medicine.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。